Abbott (NYSE:ABT) warned surgeons earlier this month about a potential issue with its MitraClip after receiving 9 reports of problems that led to surgical interventions.
In a Feb. 4 urgent field safety notice, Abbott Vascular said the reports indicated that the delivery system for the MitraClip device, which is designed to repair the heart’s mitral valve, malfunctioned during implantation procedures. In 1 of the cases the patient died after the procedure due to “severe comorbidities,” according to the notice.
